CADL · Candel Therapeutics Inc
United States · RS rating 66 · As of 2026-10-14
| Price | 9.07 USD |
|---|---|
| 1-day change | -2.2% |
| RS rating (overall / 1M / 3M / 12M) | 66 / 13 / 46 / 86 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 34 / 50 / 17 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -157.1% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +34.0% |
| Market cap (USD) | $515.7M |